Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Bussiness Awards 2024

Sharon and Orlaith were recently awarded the Irish Times Future Leaders award

February 24th 2025

Read More

San Bridge

We are attending the JP Morgan Healthcare Conference 2025 in San Francisco January 13-16. We look forward to meeting you there.

February 20th 2025December 9th 2024

Read More

EY

Shorla Oncology co-founders win EY Entrepreneurs of the Year award

December 2nd 2024

Read More

Logo

Shorla Oncology Announces FDA Approval of IMKELDI (imatinib mesylate)

November 26th 2024November 26th 2024

Read More

Logo

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

November 21st 2024

Read More

Shorla Oncology

Shorla Oncology will be attending The (ACR) Convergence 2024 in Washington DC from Nov 14-19

November 13th 2024

Read More

Shorla Oncology

Shorla Oncology at ASHP Mid Year 2024, New Orleans, Dec 8-12

November 13th 2024November 11th 2024

Read More

Banner

Frontiers Health 2024

October 10th 2024

Read More

Banner

Shorla Oncology at CPHI Milan

September 23rd 2024

Read More

Older posts
Newer posts
Page1 Page2 Page3 Page4 … Page13
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.